- Split View
-
Views
-
Cite
Cite
Stefan Remy, Heinz Beck, Molecular and cellular mechanisms of pharmacoresistance in epilepsy, Brain, Volume 129, Issue 1, January 2006, Pages 18–35, https://doi.org/10.1093/brain/awh682
- Share Icon Share
Abstract
Epilepsy is a common and devastating neurological disorder. In many patients with epilepsy, seizures are well-controlled with currently available anti-epileptic drugs (AEDs), but a substantial (∼30%) proportion of patients continue to have seizures despite carefully optimized drug treatment. Two concepts have been put forward to explain the development of pharmacoresistance. The transporter hypothesis contends that the expression or function of multidrug transporters in the brain is augmented, leading to impaired access of AEDs to CNS targets. The target hypothesis holds that epilepsy-related changes in the properties of the drug targets themselves may result in reduced drug sensitivity. Recent studies have started to dissect the molecular underpinnings of both transporter- and target-mediated mechanisms of pharmacoresistance in human and experimental epilepsy. An emerging understanding of these underlying molecular and cellular mechanisms is likely to provide important impetus for the development of new pharmacological treatment strategies.
Introduction to the clinical problem of pharmacoresistance in epilepsy
Epilepsy is a common and devastating neurological disorder. In many patients with epilepsy, seizures are well-controlled with currently available anti-epileptic drugs (AEDs). However, seizures persist in a considerable proportion of these patients. The exact fraction of epilepsy patients who are considered refractory varies in the literature, mostly because the criteria for classification as pharmacoresistant have varied. Nevertheless, a substantial proportion (∼30%) of epilepsy patients do not respond to any of two to three first-line AEDs, despite administration in an optimally monitored regimen (Regesta and Tanganelli, 1999). The fraction of patients who are pharmacoresistant appears to correlate with certain features of the epileptic condition, such as a high seizure frequency or febrile seizures prior to treatment, early onset of seizures or the presence of certain types of structural brain lesions. In addition, pharmacoresistance occurs frequently in patients with partial seizures (Aicardi and Shorvon, 1997; Regesta and Tanganelli, 1999 for a more complete discussion of clinical aspects of pharmacoresistance). Despite the obvious clinical relevance of uncontrolled seizures in a large fraction of epilepsy patients, the cellular basis of pharmacoresistance has so far remained elusive. The availability of tissue from epilepsy patients undergoing surgery for focal epilepsies, primarily temporal lobe epilepsy, has allowed to address some of the mechanisms underlying pharmacoresistance of focal epilepsies. The mechanisms underlying the development of resistance in certain forms of generalized epilepsies are still enigmatic.
Introduction to the cellular candidate mechanisms of pharmacoresistance
Which key mechanisms govern efficacy of CNS drugs? Firstly, in the presence of adequate, carefully monitored serum AED levels, drugs have to traverse the blood–brain barrier (BBB). Subsequently, CNS activity of AEDs is determined by a multitude of factors, including physical properties, such as lipophilicity, that affect their distribution in different compartments within the CNS. Consequently, one scenario to explain pharmacoresistance could be that sufficient intraparenchymal AED concentrations are not attained, even in the presence of adequate AED serum levels. Such a phenomenon could arise via an enhanced function of multidrug transporters that control intraparenchymal AED concentrations (transporter hypothesis of pharmacoresistance, Kwan and Brodie, 2005).
Following permeation into the CNS parenchyma, drugs have to bind to one or more target molecules to exert their desired action. Thus, pharmacoresistance may also be caused by a modification of one or more drug target molecules (seeTable 1). These modifications would then cause a reduced efficacy of a given AED at the target. This concept has been collectively termed the target hypothesis of pharmacoresistance (Fig. 1).
Target . | Modification . | Cell type . | Human data (yes/no) . |
---|---|---|---|
Voltage-gated sodium channels | Downregulation of accessory subunits | Dentate granule cells | Yes |
CA1 pyramidal neurons | |||
Altered alpha subunit expression, induction of neonatal isoforms | CA1 pyramidal neurons | Yes | |
CA3 pyramidal neurons | |||
Dentate granule cells | |||
Voltage-gated calcium channels | Increased expression of T-type channels | CA1 pyramidal neurons | No |
Hyperpolarization-activated current (IH) | Loss of dendritic IH | Entorhinal cortex layer 3 neurons | No |
GABA receptors | GABAA receptors: decrease of α1 subunits increase of α4 subunits | Dentate granule cells | Yes |
P-Glycoprotein (MDR1) | Overexpression | Astrocytes | Yes |
Capillary endothelial cells | |||
Neurons | |||
MRP1 | Overexpression | Astrocytes | Yes |
Neurons | |||
MRP2 | Overexpression | Astrocytes | Yes |
Capillary endothelial cells | |||
MVP (major vault protein) | Overexpression | Microglial cells | No |
Target . | Modification . | Cell type . | Human data (yes/no) . |
---|---|---|---|
Voltage-gated sodium channels | Downregulation of accessory subunits | Dentate granule cells | Yes |
CA1 pyramidal neurons | |||
Altered alpha subunit expression, induction of neonatal isoforms | CA1 pyramidal neurons | Yes | |
CA3 pyramidal neurons | |||
Dentate granule cells | |||
Voltage-gated calcium channels | Increased expression of T-type channels | CA1 pyramidal neurons | No |
Hyperpolarization-activated current (IH) | Loss of dendritic IH | Entorhinal cortex layer 3 neurons | No |
GABA receptors | GABAA receptors: decrease of α1 subunits increase of α4 subunits | Dentate granule cells | Yes |
P-Glycoprotein (MDR1) | Overexpression | Astrocytes | Yes |
Capillary endothelial cells | |||
Neurons | |||
MRP1 | Overexpression | Astrocytes | Yes |
Neurons | |||
MRP2 | Overexpression | Astrocytes | Yes |
Capillary endothelial cells | |||
MVP (major vault protein) | Overexpression | Microglial cells | No |
Target . | Modification . | Cell type . | Human data (yes/no) . |
---|---|---|---|
Voltage-gated sodium channels | Downregulation of accessory subunits | Dentate granule cells | Yes |
CA1 pyramidal neurons | |||
Altered alpha subunit expression, induction of neonatal isoforms | CA1 pyramidal neurons | Yes | |
CA3 pyramidal neurons | |||
Dentate granule cells | |||
Voltage-gated calcium channels | Increased expression of T-type channels | CA1 pyramidal neurons | No |
Hyperpolarization-activated current (IH) | Loss of dendritic IH | Entorhinal cortex layer 3 neurons | No |
GABA receptors | GABAA receptors: decrease of α1 subunits increase of α4 subunits | Dentate granule cells | Yes |
P-Glycoprotein (MDR1) | Overexpression | Astrocytes | Yes |
Capillary endothelial cells | |||
Neurons | |||
MRP1 | Overexpression | Astrocytes | Yes |
Neurons | |||
MRP2 | Overexpression | Astrocytes | Yes |
Capillary endothelial cells | |||
MVP (major vault protein) | Overexpression | Microglial cells | No |
Target . | Modification . | Cell type . | Human data (yes/no) . |
---|---|---|---|
Voltage-gated sodium channels | Downregulation of accessory subunits | Dentate granule cells | Yes |
CA1 pyramidal neurons | |||
Altered alpha subunit expression, induction of neonatal isoforms | CA1 pyramidal neurons | Yes | |
CA3 pyramidal neurons | |||
Dentate granule cells | |||
Voltage-gated calcium channels | Increased expression of T-type channels | CA1 pyramidal neurons | No |
Hyperpolarization-activated current (IH) | Loss of dendritic IH | Entorhinal cortex layer 3 neurons | No |
GABA receptors | GABAA receptors: decrease of α1 subunits increase of α4 subunits | Dentate granule cells | Yes |
P-Glycoprotein (MDR1) | Overexpression | Astrocytes | Yes |
Capillary endothelial cells | |||
Neurons | |||
MRP1 | Overexpression | Astrocytes | Yes |
Neurons | |||
MRP2 | Overexpression | Astrocytes | Yes |
Capillary endothelial cells | |||
MVP (major vault protein) | Overexpression | Microglial cells | No |
Modification in drug targets as basis for pharmacoresistance
The cellular mechanisms of AEDs have been examined to some extent in normal brain tissue, or ion channels and receptors in expression systems. These data are summarized qualitatively in Table 2. Many of these drug targets are altered on a molecular level in epilepsy. In the following sections, we will attempt to summarize briefly the known mechanisms of AEDs on ion channels. We will then focus on emerging experimental evidence supporting a loss of AED efficacy at selected targets, and discuss the possible molecular basis of these findings.
Changes in molecular drug targets for AEDs
Voltage-gated Na+ channels
Voltage-gated Na+ currents are ubiquitously expressed in excitable cells (Fig. 2A, Goldin, 1999; Goldin et al., 2002), and appear to be targets for multiple first-line AEDs. Upon depolarization of the membrane, the channels activate and give rise to a fast ‘transient’ inward Na+ current (INaT, Fig. 2B), responsible for the rising phase of the action potential, and—in some cells—a slowly-inactivating ‘persistent’ current (INaP, seeFig. 2C). Both current components represent major targets of several first-line AEDs including carbamazepine, phenytoin (PHT), lamotrigine and valproate (Ragsdale and Avoli, 1998; Catterall, 1999; Köhling, 2002, see also Table 2).
Most AEDs block Na+ channels in their resting state (tonic block) at hyperpolarized membrane potentials (Ragsdale and Avoli, 1998), with a voltage-dependent enhancement of the block towards more depolarizing potentials. This voltage-dependent inhibition is associated with a shift of the steady-state inactivation curve in a hyperpolarized direction (Fig. 2D). Importantly, blocking effects are activity- or use-dependent, i.e. blocking effects are enhanced when neurons are repetitively depolarized at higher frequencies (Fig. 2E and F). This activity-dependence is expressed as a slowing of recovery from fast Na+ channel inactivation (Ragsdale and Avoli, 1998; Catterall, 1999). It has been suggested that use-dependent blocking effects are important because they result in a preferential block of INaT during prolonged high-frequency neuronal activity, such as that occurring during seizures.
Several lines of evidence so far have indicated that reduced efficacy in inhibiting INaT may be a candidate mechanism of pharmacoresistance to some AEDs. Firstly, in CA1 neurons, the effects of carbamazepine on the steady-state inactivation properties of INaT were transiently reduced in the kindling model of epilepsy (Vreugdenhil and Wadman, 1999b). In contrast to these comparatively modest and transient effects, a complete and long-lasting loss of use-dependent blocking effects of carbamazepine was found in the pilocarpine model of epilepsy in hippocampal dentate granule cells, as well as in epilepsy patients with carbamazepine-resistant temporal lobe epilepsy (Remy et al., 2003a). This dramatic loss of a major mechanism of action of carbamazepine did not extend to other AEDs known to affect INaT. Following pilocarpine-induced status epilepticus, the use-dependent effects of PHT were reduced, but not completely lost, while the effects of lamotrigine were completely unchanged (Remy et al., 2003b). Although the mechanisms of INaT inhibition induced by valproate are still controversial (Xie et al., 2001); but see (Vreugdenhil et al., 1998; Vreugdenhil and Wadman, 1999b), this substance exhibits potent voltage-dependent blocking effects in various preparations (Fohlmeister et al., 1984; Zona and Avoli, 1990; Vreugdenhil and Wadman, 1999b; Köhling, 2002). Notably, in tissue obtained from pharmacoresistant patients and in experimental epilepsy no differences regarding valproic acid effects on INaT could be observed (Vreugdenhil et al., 1998; Vreugdenhil and Wadman, 1999b; Remy et al., 2003b). Collectively, these results suggest that epileptogenesis causes changes in the properties of INaT that may differ depending on the cell type examined (i.e. dentate granule cells versus CA1 neurons), and according to the epilepsy model studied. Changes in INaT may then dramatically affect sensitivity to some, but not all, AEDs.
Block of INaP may also be a crucially important mechanism of AED action. Pharmacological augmentation of INaP causes an increased propensity of individual neurons to generate burst discharges (Su et al., 2001), and several mutations that give rise to increased INaP cause epilepsy in mice or humans (Kearney et al., 2001; Lossin et al., 2002; Rhodes et al., 2004; Spampanato et al., 2004). INaP is efficiently blocked by many AEDs, frequently at a concentration range lower than that observed for INaT (Köhling, 2002). In native neurons, INaP is potently inhibited by lamotrigine and PHT, as well as losigamone (Chao and Alzheimer, 1995; Lampl et al., 1998; Gebhardt et al., 2001; S. Remy and H. Beck, unpublished data). Despite the potential importance of INaP in the regulation of neuronal firing, altered AED effects on INaP following epileptogenesis have so far not been described.
What mechanisms can account for an altered sensitivity of Na+ channels in epileptic tissue? One possibility may be that the subunit composition of these channels is altered, such that the expression of AED-insensitive subunits or subunit combinations is promoted. Indeed, numerous changes in Na+ channel subunit expression have been observed in both human and experimental epilepsy (Bartolomei et al., 1997; Aronica et al., 2001; Whitaker et al., 2001; Ellerkmann et al., 2003). In this respect, the downregulation of accessory Na+ channel β1 and β2 subunits following experimentally induced status epilepticus appears to be a consistent finding (Gastaldi et al., 1998; Ellerkmann et al., 2003). In addition to changes in mRNA levels, altered alternative splicing of pore-forming subunit mRNAs has also been observed (Gastaldi et al., 1997; Aronica et al., 2001). A recent, very interesting study underscores the potential importance of the β1 subunit in the development of pharmacoresistance. In the paper by Lucas et al. (2005), the pharmacology of Na+ channels containing a mutant β1 subunit causing the epilepsy syndrome generalized epilepsy with febrile seizures plus was examined. Surprisingly, Na+ channels containing mutant β1 subunits displayed a dramatic and selective loss of use-dependent block by the AED PHT, that was very similar to the effects observed in chronic experimental epilepsy for PHT and carbamazepine (Remy et al., 2003a, b). These results collectively suggest that changes in accessory subunits might be promising candidates for further investigation as a molecular correlate of the AED-insensitive sodium channel. They are also intriguing because they suggest that use-dependent effects on Na+ channels require some form of interaction with β1 subunits, whereas this may not be the case for tonic block of Na+ channels.
It is at present unclear why use-dependent block by carbamazepine and PHT is lost or reduced, whereas use-dependent block by lamotrigine remains intact in experimental epilepsy. This is an intriguing question because it has been suggested that all three drugs bind to the same site on Na+ channels in CA1 neurons based on coapplication experiments (Kuo et al., 1998). The mutual exclusivity among the binding of drugs simultaneously applied to a channel may however result from either an allosteric mechanism or from direct competition of the drugs at a single binding site. Even though a single binding site appears to provide the most parsimonious explanation for these results, it is quite conceivable that allosteric interactions between different binding sites may also exist. This would provide a basis for the AED-selective loss of sensitivity observed in chronic experimental epilepsy.
Other types of voltage-gated channels
Other types of voltage-gated channels have also been screened as potential drug targets. In many cases, effects of AEDs on specific ion channel subunits or ion channels in native neurons or expression systems have been described (seeTable 2).
Ca2+ channels can be subdivided into two groups: high-threshold Ca2+ currents, and a group of low-threshold currents (also termed T-type Ca2+ currents, Ertel et al., 2000). A number of AEDs has been shown to inhibit high threshold Ca2+ channels in native neurons at high therapeutic concentrations (Stefani et al., 1997b, 1998; Schumacher et al., 1998; seeTable 2). Additionally, the AED gabapentin has been shown to exhibit strong and specific binding to the accessory α2δ subunit (Gee et al., 1996). It has been proposed that this effect underlies inhibition of presynaptically expressed high-threshold Ca2+ channels by gabapentin, which causes a reduction in neurotransmitter release (Fink et al., 2000; seeTable 2). Some AEDs potently inhibit low-threshold T-type Ca2+ channels, which are not expressed presynaptically (Yaari et al., 1987; Coulter et al., 1989; Gomora et al., 2001; seeTable 2). The effects of AEDs on the three T-type Ca2+ channel subunits, as well as in native neurons, are diverse (cf. Todorovic and Lingle, 1998; Todorovic et al., 2000; Lacinova, 2004). T-type channels are critically important in controlling the excitability of the postsynaptic compartment of neurons (Huguenard, 1996), both in normal and epileptic neurons. For instance, aberrant bursting is seen in CA1 hippocampal neurons from epileptic animals (Sanabria et al., 2001) that is mediated by increased expression of T-type Ca2+ channels (Su et al., 2002). Additionally, T-type Ca2+ channels in thalamic neurons have been implicated in the generation of spike-wave discharges in absence epilepsy (Huguenard, 2002 and references therein). Consequently, inhibition of burst discharges in thalamic neurons is thought to contribute to the anti-epileptic effects of antiabsence AEDs. It is so far unknown if the sensitivity of either presynaptic or post-synaptic Ca2+ channels to AEDs changes during epileptogenesis. The same applies to other voltage-gated ion channels such as K+ channels (seeTable 2).
H-currents (IH) are mixed cationic currents that are activated by hyperpolarization and deactivated following repolarization of the membrane. IH has multiple functional roles; for instance, it mediates some forms of pacemaker activity in heart and brain, it regulates membrane resistance and dendritic integration and stabilizes the level of the resting potential (reviewed, Robinson and Siegelbaum, 2003). An interesting feature of IH appears to be that the corresponding channels are predominantly located in dendrites, rather than the soma of neurons (Poolos et al., 2002). Interestingly, dendritic H-currents are potently enhanced by the AEDs lamotrigine and gabapentin at clinically relevant concentrations (Poolos et al., 2002; Surges et al., 2003, seeTable 2), resulting in IH-mediated inhibitory effects on action potential firing by selectively reducing the excitability of the apical dendrites (Poolos et al., 2002). Cell-type specific changes in IH have been described in models of epilepsy (Chen et al., 2001), including a dramatic loss of dendritic IH in entorhinal cortex neurons (Shah et al., 2004). The importance of this change for pharmacoresistance to lamotrigine has not been directly addressed, but it is conceivable that a sufficiently large reduction of these channels could constitute a de facto loss of a major drug target for lamotrigine in this subregion.
Neurotransmitter systems: GABA
GABA is the predominant inhibitory neurotransmitter in the adult brain and plays a critical role in the regulation of excitability of neuronal networks (Mody and Pearce, 2004). GABA binding to ionotropic GABAA receptors causes opening of the receptor ionophore, which is permeable to Cl− and—to a lesser extent—to HCO3. In the presence of a normal adult transmembraneous Cl− gradient, this results in expression of an inhibitory post-synaptic current that hyperpolarizes the post-synaptic neuronal membrane. Direct modulators of GABAA receptors include benzodiazepines and barbiturates. Benzodiazepines increase GABA affinity of the receptor complex and may augment their Cl− conductance via allosteric modulation (Twyman et al., 1989a; Rudolph et al., 1999, 2001). Substances that interact with the GABA system in a more indirect way affect the handling and metabolism of synaptically released GABA. Vigabatrin (gamma-vinyl GABA) is a GABA analogue that inhibits one of the main enzymes controlling GABA concentrations in the brain, GABA transaminase. Consequently, application of vigabatrin causes large elevations in brain GABA levels. The AED tiagabine inhibits the high-affinity GABA transporter GAT1 that normally terminates synaptic action of GABA via rapid uptake. So far, available evidence indicates that neither the efficacy of GABA uptake, nor its sensitivity to tiagabine is altered in chronic experimental epilepsy (Frahm et al., 2003).
Regarding GABAA receptor agonists, reduced activity of such substances has been described in a chronic model of epilepsy. In the pilocarpine model of epilepsy, GABAA receptors of dentate granule cells show a reduced sensitivity to drugs acting on the benzodiazepine receptor site 1. While augmentation of GABA-evoked currents by the broad-spectrum benzodiazepine clonazepam was slightly enhanced in epileptic animals, augmentation by the benzodiazepine site 1-selective agonist zolpidem was strongly decreased (Gibbs et al., 1997; Brooks-Kayal et al., 1998; Cohen et al., 2003). In CA1 pyramidal cells, the effects of clonazepam were dramatically reduced in chronically epileptic animals (81% reduction relative to control, (Gibbs et al., 1997). This suggests that the same might also apply to clinically employed benzodiazepines.
What is the molecular mechanism of this change in GABAA receptor pharmacosensitivity? An enormous diversity of GABAA receptors has been reported in the CNS, reflecting the fact that in each receptor at least three different subunits are present, which derive from one of eight structurally distinct and genetically distinct families (Costa, 1998; Sperk et al., 2004). Combined molecular and functional studies indicate that a transcriptionally mediated switch in the alpha subunit composition of GABAA receptors occurs in epileptic animals, in particular a decrease of α1 subunits and an increase of α4 subunits (Brooks-Kayal et al., 1998). These findings correlate well with the observed changes in benzodiazepine receptor pharmacology.
Neurotransmitter systems: glutamate
Despite the undoubted importance of altered glutamate-mediated excitatory neurotransmission in chronic experimental (Mody and Heinemann, 1987; Martin et al., 1992; Kohr et al., 1993) and human epilepsy (Isokawa and Levesque, 1991), few substances acting on this system have been developed to clinical use so far. Felbamate exerts complex effects on the NMDA receptor (Kuo et al., 2004), some of which may be mediated via the modulatory glycine binding site (White et al., 1995). Some of the effects of felbamate have been shown to be affected by NMDA receptor subunit composition (Kleckner et al., 1999; Harty and Rogawski, 2000). AEDs acting on AMPA receptors are also scarce, some drugs currently in clinical trials inhibit AMPA receptors (talampanel, seeChappell et al., 2002). Likewise, topiramate has been shown to reduce excitatory synaptic transmission via an inhibition of AMPA receptors (Qian and Noebels, 2003). Altered cellular expression of glutamate receptors in epilepsy should be considered in future development of compounds acting on these receptors. Given the paucity of established AEDs acting on individual glutamate receptors, however, we will abstain from an in depth discussion of these changes here.
Role of changes in drug targets in the setting of a chronically epileptic brain
The specific changes in drug targets described above are an attractive concept to explain pharmacoresistance. It is important to realize, however, that not only changes in drug targets themselves, but also changes in other molecules that affect their function may have important consequences for AED efficacy. This idea is exemplified by recent findings regarding the role of GABA in epilepsy. GABA may on occasion act as an excitatory neurotransmitter in the immature brain. A depolarizing action of GABAA receptor activation arises because of an altered chloride homeostasis, resulting in a changed chloride gradient across the neuronal membrane. The altered chloride reversal potential then results in a net outward flux of Cl− through the GABAA receptor ionophore, causing depolarization of the neuron (Mody and Pearce, 2004). Interestingly, in addition to the developing brain, depolarizing GABA responses appear to be a feature of some neurons in the epileptic brain (Cohen et al., 2002; Wozny et al., 2003). Augmenting such depolarizing GABA-mediated potentials by application of GABA agonists is likely to facilitate action potential generation to excitatory input (Gulledge and Stuart, 2003), and thereby would increase neuronal excitability instead of decreasing it. Whether depolarizing GABA responses really play a role in pharmacoresistance to GABAmimetic drugs remains to be seen. These considerations do, however, illustrate the need to consider changes in drug targets within the more general setting of a chronically epileptic brain.
Molecular mechanisms underlying altered target sensitivity
So far, most of the mechanisms implicated in altered AED targets are changes in the transcription of ion channel subunits. Seizures appear to cause a highly coordinated change in transcription of certain groups of ion channel subunits, both in rat models of epilepsy (Brooks-Kayal et al., 1998) and in human epilepsy patients (Brooks-Kayal et al., 1999; Bender et al., 2003). This seizure-induced transcriptional plasticity appears to be differentially regulated in different neuron types (cf. Bender et al., 2003; Shah et al., 2004). These transcriptional changes most probably affect both the density of ion channels in the neuronal membrane, as well as the subunit stochiometry of multisubunit channel complexes (Brooks-Kayal et al., 1998). In addition to transcriptional mechanisms, seizure activity may also evoke multiple post-translational modifications of ion channel proteins, such as altered protein transport and targeting, phosphorylation or glycosylation (Bernard et al., 2004). Indeed, increased phosphorylation of INa by protein kinase C has been shown to affect responsiveness to the AED topiramate in one study (Curia et al., 2004). It is quite possible that other post-transcriptional modifications of ion channel proteins induced by seizures may profoundly affect their drug sensitivity. How seizures may modify the pharmacosensitivity of AED targets is summarized schematically in Fig. 3.
Relationship of molecular changes in AED sensitivity to pharmacoresistance observed in vivo
How is the loss of AED sensitivity on the level of an ion channel such as INaT related to pharmacoresistance observed in human epilepsy patients or intact animals? In epilepsy patients, properties of INaT seemed to differ when patients are separated into two groups, one resistant to carbamazepine and a smaller one responsive to carbamazepine. In the former, the use-dependent block of INaT proved to be abolished, similar to the findings in the pilocarpine model of epilepsy. In contrast, carbamazepine responsive patients showed potent use-dependent effects of carbamazepine on INaT. Thus, the sensitivity to carbamazepine on a cellular level appeared to correlate with the clinical responsiveness to the same drug. These results should be interpreted with caution on two levels. Firstly, the number of patients for which both clinical and in vitro data could be obtained is still limited, particularly when considering the group of pharmacoresponsive epilepsy patients (Remy et al., 2003a). Secondly, patients who are resistant to carbamazepine very frequently are resistant also to other AEDs (Kwan and Brodie, 2000). However, available data indicate that altered sensitivity of Na+ channels may not be able to account for altered efficacy of other AEDs such as valproic acid or lamotrigine (Remy et al., 2003b). This finding may indicate that resistance to AEDs in epilepsy patients is a complex phenomenon that possibly relies on multiple mechanisms. On a genetic level, association studies are beginning to yield candidate gene polymorphisms that may be associated with AED sensitivity (Tate et al., 2005).
The correlation of target pharmacosensitivity and sensitivity to AEDs in vivo in experimental models of epilepsy is quite unclear. The pilocarpine model of epilepsy has been frequently used to study changes in pharmacosensitivity of drug targets. Leite and Cavalheiro (1995) have provided some evidence that high doses of common AEDs such as carbamazepine, PHT and valproate reduce the spontaneous seizure frequency in these animals. This is in apparent contradiction to the finding that Na+ channels in the same model are resistant to carbamazepine. It is possible that this may be due to the high doses of AEDs used, or alternatively to differences in the rat strains and/or pilocarpine protocols used. Furthermore, it is likely that some groups responsive and resistant to AED may exist in chronic epilepsy models (Löscher et al., 1998; Nissinen and Pitkänen, 2000). Ideally, these questions could, therefore, be resolved by first examining pharmacosensitivity in intact animals, and subsequently comparing these in vivo results to the cellular effects of AEDs in the same individuals. So far, this important approach has only been implemented in few experiments (Jeub et al., 2002). For these experiments, kindled rats were used that could be separated into two groups based on their responsiveness to PHT (Löscher et al., 1998). When rats responsive to PHT were compared to a group of rats that were not, no difference in PHT sensitivity of INaT emerged. It should be noted, however, that PHT effects on the recovery from inactivation and use-dependent block, where the most dramatic effects were seen in the pilocarpine model of epilepsy, were not examined in this study (Jeub et al., 2002). Nevertheless, animal models in which groups with differential pharmacosensitivity can be defined represent a promising avenue to study mechanisms of pharmacoresistance (Nissinen and Pitkänen, 2000). It remains to be seen how far such animal models mirror mechanisms of pharmacoresistance in human epilepsy patients.
Modification in multidrug transporters as basis for pharmacoresistance
Overview of multidrug transporter molecules expressed in the brain
The second main emerging concept to explain pharmacoresistance contends that increased expression or function of multidrug transporter proteins decreases the effective concentration of AEDs at their targets (seeFig. 1B). Intense interest has been focused on understanding the molecular basis of multidrug transport in the brain in recent years, primarily because of their potential importance in mediating resistance to anticancer drugs. This effort has led to the discovery of several genes encoding transmembrane proteins that function as drug efflux pumps. These genes are highly conserved and the vast majority belongs to the superfamily of adenosine triphosphate-binding cassette (ABC) proteins. A large number of human genes belonging to this superfamily have been identified, which have been systematically classified into seven subfamilies [ABCA, ABCB, ABCC, ABCD, ABCE ABCF and ABCG (Dean et al., 2001)]. Most of these genes encode ATP-driven pumps that are able to transport a wide range of substrates.
Studies addressing the role of multidrug transporters in the development of pharmacoresistant epilepsy have hitherto been focused mainly on a subset of these transporters. MDR1 (belonging to the ABCB subfamily, systematic nomenclature ABCB1) encodes P-glycoprotein (PGP, Silverman et al., 1991; Ueda et al., 1993), which transports a wide range of lipophilic substances across cell membranes. A further family of genes [multidrug-resistance associated proteins or MRPs, systematic nomenclature ABCC subfamily (Borst et al., 2000)] transports a range of substances partially overlapping with those transported by PGP. Most of the proteins encoded by these genes (i.e. MRP1 to 6 and PGP) are expressed in endothelial cells of the blood–brain or blood–CSF barrier (Schinkel et al., 1996; Huai-Yun et al., 1998; Rao et al., 1999; Zhang et al., 1999). In addition, MRP1 and one of the two rodent isoforms of PGP are present in astrocytes (Pardridge et al., 1997; Regina et al., 1998; Golden and Pardridge, 1999; Decleves et al., 2000). The functional role of this expression is currently a matter of debate (Golden and Pardridge, 2000).
Altered expression of multidrug transporters in human and experimental epilepsy, and consequences for intraparenchymal AED concentrations
Several lines of evidence indicate a role of multidrug transporters in the development of resistance to AEDs, which are set out in more detail as follows. Firstly, drug transporters transport some AEDs in isolated cell systems (Batrakova et al., 1999; Marchi et al., 2004). Secondly, drug transporters appear to regulate intraparenchymal drug concentrations in vivo in many cases. Mice or rats lacking certain drug transporters display increased accumulation of AEDs (Schinkel et al., 1996, 1997; Rizzi et al., 2002; Potschka et al., 2003b, but see Sills et al., 2002; seeTable 3). It should be noted that interpretation of data from such animal models is complicated by two issues: firstly, there may be a compensatory regulation of other drug transporter molecules and, secondly, the wide expression of drug transporters in other tissues may result in complex pharmacokinetic effects of deleting drug transporter genes. These issues do not apply when drug transporters are inhibited pharmacologically in vivo. Indeed, pharmacological inhibition of drug transporters alters brain distribution of some AEDs (Potschka and Löscher, 2001; Potschka et al., 2001, 2003b; Löscher and Potschka, 2002, seeTable 3). It should be stated, however, that the drug transporter inhibitors employed thus far are not very specific, and that studies using more specific novel inhibitors are currently being undertaken.
Drug efflux transporter . | Substrate . |
---|---|
PGP (MDR1, ABCB1) | Phenytoin (Tishler et al., 1995; Schinkel et al., 1996; Potschka and Löscher, 2001; Rizzi et al., 2002) |
Carbamazepine (Potschka et al., 2001) | |
Phenobarbital (Potschka et al., 2002) | |
Lamotrigine (Potschka et al., 2002) | |
Felbamate (Potschka et al., 2002) | |
Topiramate (Sills et al., 2002) | |
MRP2 (ABCC2) | Phenytoin (Potschka et al., 2003b) |
Drug efflux transporter . | Substrate . |
---|---|
PGP (MDR1, ABCB1) | Phenytoin (Tishler et al., 1995; Schinkel et al., 1996; Potschka and Löscher, 2001; Rizzi et al., 2002) |
Carbamazepine (Potschka et al., 2001) | |
Phenobarbital (Potschka et al., 2002) | |
Lamotrigine (Potschka et al., 2002) | |
Felbamate (Potschka et al., 2002) | |
Topiramate (Sills et al., 2002) | |
MRP2 (ABCC2) | Phenytoin (Potschka et al., 2003b) |
Drug efflux transporter . | Substrate . |
---|---|
PGP (MDR1, ABCB1) | Phenytoin (Tishler et al., 1995; Schinkel et al., 1996; Potschka and Löscher, 2001; Rizzi et al., 2002) |
Carbamazepine (Potschka et al., 2001) | |
Phenobarbital (Potschka et al., 2002) | |
Lamotrigine (Potschka et al., 2002) | |
Felbamate (Potschka et al., 2002) | |
Topiramate (Sills et al., 2002) | |
MRP2 (ABCC2) | Phenytoin (Potschka et al., 2003b) |
Drug efflux transporter . | Substrate . |
---|---|
PGP (MDR1, ABCB1) | Phenytoin (Tishler et al., 1995; Schinkel et al., 1996; Potschka and Löscher, 2001; Rizzi et al., 2002) |
Carbamazepine (Potschka et al., 2001) | |
Phenobarbital (Potschka et al., 2002) | |
Lamotrigine (Potschka et al., 2002) | |
Felbamate (Potschka et al., 2002) | |
Topiramate (Sills et al., 2002) | |
MRP2 (ABCC2) | Phenytoin (Potschka et al., 2003b) |
Interestingly, the results in the literature with regard to one of the most frequently employed AEDs, carbamazepine, are not uniform. This drug is not transported in PGP-containing cell systems, and its brain concentration remains unaltered in mice lacking PGP (Owen et al., 2001), or animals lacking MRP2 (Potschka et al., 2003a). On the other hand, pharmacological (Potschka et al., 2001) or genetic (Rizzi et al., 2002) inhibition of PGP does appear to be associated with a change in intraparenchymal carbamazepine concentration under some conditions. The reasons for this discrepancy are currently under scrutiny. That not all AEDs may be transported equally by drug transporters has also been suggested in the case of some benzodiazepines, which appear not to be transported by MDR1 (Schinkel et al., 1996). As a further possibility, carbamazepine has been shown to itself inhibit the activity of human P-glycoprotein, albeit at high concentrations which may not be clinically relevant (Weiss et al., 2003).
A large body of evidence suggests that different drug transporter molecules are indeed upregulated in human epilepsy, as well as in experimental models of epilepsy. For instance, increased MDR1 expression on the mRNA and/or protein level occurs in patients with different forms of epilepsy (Tishler et al., 1995; Lazarowski et al., 1999; Sisodiya et al., 1999, 2002; Aronica et al., 2003; Volk and Löscher, 2005) and after chemically-induced status epilepticus or audiogenic seizures (Zhang et al., 1999; Kwan et al., 2002; Rizzi et al., 2002). Similar findings have been obtained for MRP1 [(Sisodiya et al., 2001, 2002), MRP2 (Dombrowski et al., 2001)] and major vault protein (Van Vliet et al., 2004). These studies have also shown that expression of drug transporter genes in epileptic foci is observed in cell types that do not usually express them. For instance, PGP and MRP1 appear to be strongly upregulated on the protein level in astrocytes, especially surrounding blood vessels (Sisodiya et al., 2002). Likewise, there may be upregulation of drug transporter expression in dysplastic neurons in focal cortical dysplasia (Sisodiya et al., 2001), as well as in hippocampal neurons in temporal lobe epilepsy (Marchi et al., 2004; Volk et al., 2004). It is yet unclear how this ectopic expression might contribute to altered pharmacosensitivity. It is entirely possible, however, that expression of multidrug transporters in neuronal membranes inhibits access of AEDs to intracellular sites of action.
Relationship of molecular changes in AED sensitivity to pharmacoresistance observed in vivo
If multidrug transporters play a significant role in pharmacoresistance, then upregulation of transporters on the molecular or functional level should correlate with the clinically observed responsiveness to AEDs. Indeed, increased drug transporter expression appeared to be correlated with less efficient seizure control in one study (Tishler et al., 1995). This correlation is also found in an animal model of resistance to AEDs. Rats resistant to phenobarbital showed a dramatic overexpression of PGP in limbic brain regions compared to rats responsive to phenobarbital (Volk and Löscher, 2005). Similar findings have been obtained in an elegant study using MRP2-deficient rats. In this study, MRP2-deficient kindled rats have higher PHT brain levels than wild-type rats, and are more susceptible to PHT treatment (Potschka et al., 2003b). These findings are interesting because they constitute the first controlled experiment in which deficiency in a specific drug transporter is associated with differential susceptibility to AED treatment.
Even though, collectively, these findings appear to support a role for multidrug transporters in pharmacoresistant epilepsy, there are a number of conceptual questions that remain enigmatic. Firstly, epileptic seizures are known to result in a disruption of the BBB, which would be expected to result in better access of AEDs to brain parenchyma despite the upregulation of multidrug transporters. Secondly, patients are in many cases treated with AEDs until CNS side effects develop. This seems to indicate that relevant CNS concentrations of AEDs are reached despite transporter upregulation, yet, these patients are resistant to treatment. This apparent discrepancy could potentially arise via local upregulation of drug transporters that only affects AED concentrations at the epileptic focus.
The genetic basis of pharmacoresistance
How can the wide spectrum of pharmacoresistance observed in human epilepsy patients and some animal models be explained? A number of recent studies have suggested that sequence variants in drug transporter or ion channel genes affect either function or expression of the corresponding proteins. In the case of drug transporters, a number of functionally relevant polymorphisms have been identified (Kerb et al., 2001a, b). Furthermore, a polymorphism (C3435T) has been identified in exon 25 of the gene encoding MDR1 that is associated with increased expression of the protein (CC-genotype). Based on these findings, Siddiqui et al. (2003) conducted a population-based association study testing the hypothesis that the C3435T polymorphism is associated with resistance to AED treatment. They found that patients with drug-resistant epilepsy were more likely to have the CC-genotype than the TT-genotype [OR 2.66, 95% CI 1.32–5.38, P = 0.006 (Siddiqui et al., 2003)]. As suggested by the authors of this study, the C3435T polymorphism by itself is very unlikely to confer a biologically relevant effect. Since this variant is localized in an extensive block of linkage disequilibrium spanning the gene, the as yet unidentified causal variant is supposed be in linkage disequilibrium with the C-allele of the C3435T polymorphism. It should be noted that the results of Siddiqui et al. (2003) have not been confirmed in a subsequent study by Tan et al. (2004). To further address how polymorphisms can contribute to drug resistance, two major obstacles will have to be overcome. Firstly, it will be necessary to address experimentally whether polymorphisms found in association studies have biologically relevant effects. Secondly, it will be necessary to significantly increase the size of carefully matched patient cohorts to increase reproducibility of such results (Soranzo et al., 2004; Cavalleri et al., 2005). Finally, it will be interesting to extend current studies to include polymorphisms in other multidrug transporters. In this respect, the development of single nucleotide polymorphism tagging for classes of genes important in resistance is a very important step that may enable screening of large numbers of patients (Ahmadi et al., 2005).
It is important to note that gene polymorphisms relevant for pharmacoresistance may occur both in promoter regions as well as in introns and exons. Gene polymorphisms within the coding regions of such genes would result in a difference in ion channel or transporter proteins that precedes the onset of epilepsy. Polymorphisms in promoter regions, which affect the transcription of such genes, may affect activity-dependent transcriptional regulation of these genes by seizures. This provides a potential mechanism for the acquisition of a pharmacoresistant phenotype during epileptogenesis in pharmacoresistant—as opposed to pharmacoresponsive—patients.
Interplay between target and transporter-mediated mechanisms
Collectively, the experimental results described in the above sections indicate that functionally relevant alterations in both AED targets and AED transporters exist. Clearly, these mechanisms are not mutually exclusive. It is entirely possible that decreased permeation of AEDs into brain tissue, in synergy with changes in targets for these drugs, mediate pharmacoresistance. This does not exclude that—for some AEDs—predominant mechanisms underlying pharmacoresistance to these drugs can be identified.
Carbamazepine, for instance, appears not to be a substrate of some multidrug transporters (Owen et al., 2001); rather, sodium channels display a potent loss of sensitivity to carbamazepine (Remy et al., 2003a). These and other results imply that expression of multidrug transporters at the BBB is not the main factor in the development of resistance, and imply a target mechanism for this drug. For other AEDs, this may be different. For instance, intraparenchymal PHT concentration is potently regulated by multidrug transporters (Potschka and Löscher, 2001; Rizzi et al., 2002; Potschka et al., 2003b), and epileptic animals lacking a multidrug transporter protein (MRP2) are more sensitive to PHT treatment than wild-type animals (Potschka et al., 2003b). In contrast, target mechanisms seem to be less important for PHT compared to carbamazepine (Jeub et al., 2002; Remy et al., 2003b). Although the evidence supporting this view is far from conclusive, it is tempting to speculate that predominant resistance mechanisms may exist for specific AEDs.
Future directions of research
What are the key pieces of evidence that we should consider to be prerequisites in order to state that drug transporters and/or altered targets play a role in the development of resistance to a given AED? We believe that the following sets of experimental results should be available: In addition, the following data on human epilepsy patients should be obtained.
Evidence that the multidrug transporter regulates intraparenchymal concentrations of the drug: this should include work with specific drug transporter inhibitors, and mice lacking specific drug transporter subtypes, as well as a combination of pharmacological and genetic inhibition of transporter function.
Evidence that multidrug transporter expression and/or transporter function is upregulated in human and experimental epilepsy. Regarding drug targets, evidence should be available that drug targets are less sensitive to a given AED in chronic epilepsy. In both cases, functional and molecular changes should correlate with AED sensitivity of seizures in experimental animals or epilepsy patients.
Evidence that genetic or pharmacological manipulation of drug transporters/drug targets affects sensitivity of spontaneous seizures to AEDs in vivo in chronic models of epilepsy.
(iv) Association of polymorphisms in drug transporter/drug target genes with clinical pharmacoresistance. This could also include association of polymorphisms with the drug transporter function or drug target pharmacology measured in vitro in tissue obtained from epilepsy surgery.
(v) Demonstration that drug transporter polymorphisms have functional effects resulting in a decreased intraparenchymal AED concentration (i.e. effects on either expression or function of drug transporter molecules). Likewise, polymorphisms in drug target genes should have demonstrable effects on expression or pharmacology of these targets.
Potential future clinical implications
Once we have obtained a detailed picture of the mechanisms underlying the development of pharmacoresistance to individual AEDs, this knowledge may become increasingly important both in drug development, as well as clinically. First, detailed information on drug target changes can be used to inform the development of new drugs for the treatment of epilepsy. Currently, identification of AEDs is performed mostly in acute seizure models in normal experimental animals. These animals do not show any of the chronic changes in ion channels or receptors discussed here, and may not represent the best models to develop novel compounds useful in human epilepsy. Targeting novel drugs to ‘epileptic’ ion channels based on information from chronic models of epilepsy or even tissue from epileptic patients represents a promising avenue for rational drug development in the future.
Information on specific resistance mechanisms might also be used to guide potential treatment with drug transporter inhibitors in conjunction with AEDs. The simplest scenario in which such substances might be used would be as comedication with an AED that is ineffective predominantly due to transporter-mediated mechanisms (depicted schematically in Fig. 4B). On the other hand, comedication with transporter inhibitors in a patient in whom resistance to an AED is predominantly target mediated (seeFig. 4C) would not be expected to be beneficial. In this case, the development of drugs that specifically act on the modified target would be the more appropriate approach. Ideally, these compounds would not be substrates of drug transporter, but could also be coadministered with transporter inhibitors. For some AEDs, both resistance mechanisms may be relevant and synergistic (Fig. 4D); in this case, strategies to overcome resistance would have to combine the approaches outlined in Fig. 4B and C. A further clinical issue that may gain more and more importance in the coming years is the identification of predictors that identify clinically resistant or responsive patient populations. If clear genetic polymorphisms in either transporter or ion channel genes can be identified that reliably predict the occurrence and the probable mechanism of drug resistance (Soranzo et al., 2004; Tan et al., 2004; Ahmadi et al., 2005), these data would obviously strongly influence initial therapy, and perhaps increase the chances of its success.
References
Ahmadi KR, Weale ME, Xue ZY, Soranzo N, Yarnall DP, Briley JD, et al. A single-nucleotide polymorphism tagging set for human drug metabolism and transport.
Aicardi J, Shorvon SD. Intractable epilepsy. In: Engel J, Pedley TA, editors. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven;
Alden KJ, Garcia J. Differential effect of gabapentin on neuronal and muscle calcium currents.
Aronica E, Yankaya B, Troost D, van Vliet EA, Lopes da Silva FH, Gorter JA. Induction of neonatal sodium channel II and III alpha-isoform mRNAs in neurons and microglia after status epilepticus in the rat hippocampus.
Aronica E, Gorter JA, Jansen GH, van Veelen CW, van Rijen PC, Leenstra S, et al. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors.
Bartolomei F, Gastaldi M, Massacrier A, Planells R, Nicolas S, Cau P. Changes in the mRNAs encoding subtypes I, II and III sodium channel alpha subunits following kainate-induced seizures in rat brain.
Batrakova EV, Li S, Miller DW, Kabanov AV. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers.
Ben Menachem E. Pregabalin pharmacology and its relevance to clinical practice.
Bender RA, Soleymani SV, Brewster AL, Nguyen ST, Beck H, Mathern GW, et al. Enhanced expression of a specific hyperpolarization-activated cyclic nucleotide-gated cation channel (HCN) in surviving dentate gyrus granule cells of human and experimental epileptic hippocampus.
Bernard C, Anderson A, Becker A, Poolos NP, Beck H, Johnston D. Acquired dendritic channelopathy in temporal lobe epilepsy.
Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins.
Brooks-Kayal AR, Shumate MD, Jin H, Rikhter TY, Coulter DA. Selective changes in single cell GABA(A) receptor subunit expression and function in temporal lobe epilepsy.
Brooks-Kayal AR, Shumate MD, Jin H, Lin DD, Rikhter TY, Holloway KL, et al. Human neuronal gamma-aminobutyric acid(A) receptors: coordinated subunit mRNA expression and functional correlates in individual dentate granule cells.
Catterall WA. Molecular properties of brain sodium channels: an important target for anticonvulsant drugs.
Cavalleri GL, Lynch JM, Depondt C, Burley MW, Wood NW, Sisodiya SM, et al. Failure to replicate previously reported genetic associations with sporadic temporal lobe epilepsy: where to from here?
Chao TI, Alzheimer C. Effects of phenytoin on the persistent Na+ current of mammalian CNS neurones.
Chappell AS, Sander JW, Brodie MJ, Chadwick D, Lledo A, Zhang D, et al. A crossover, add-on trial of talampanel in patients with refractory partial seizures.
Chen K, Aradi I, Thon N, Eghbal-Ahmadi M, Baram TZ, Soltesz I. Persistently modified h-channels after complex febrile seizures convert the seizure-induced enhancement of inhibition to hyperexcitability.
Cohen I, Navarro V, Clemenceau S, Baulac M, Miles R. On the origin of interictal activity in human temporal lobe epilepsy in vitro.
Cohen AS, Lin DD, Quirk GL, Coulter DA. Dentate granule cell GABA(A) receptors in epileptic hippocampus: enhanced synaptic efficacy and altered pharmacology.
Costa E. From GABAA receptor diversity emerges a unified vision of GABAergic inhibition.
Coulter DA, Huguenard JR, Prince DA. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons.
Curia G, Aracri P, Sancini G, Mantegazza M, Avanzini G, Franceschetti S. Protein-kinase C-dependent phosphorylation inhibits the effect of the antiepileptic drug topiramate on the persistent fraction of sodium currents.
Dalby NO. GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors.
Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily.
Decleves X, Regina A, Laplanche JL, Roux F, Boval B, Launay JM, et al. Functional expression of P-glycoprotein and multidrug resistance-associated protein (Mrp1) in primary cultures of rat astrocytes.
Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, Bingaman W, et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy.
Eghbali M, Curmi JP, Birnir B, Gage PW. Hippocampal GABA(A) channel conductance increased by diazepam.
Ellerkmann RK, Remy S, Chen J, Sochivko D, Elger CE, Urban BW, et al. Molecular and functional changes in voltage-dependent Na+ channels following pilocarpine-induced status epilepticus in rat dentate granule cells.
Ertel EA, Campbell KP, Harpold MM, Hofmann F, Mori Y, Perez-Reyes E, et al. Nomenclature of voltage-gated calcium channels.
Ffrench-Mullen JM, Barker JL, Rogawski MA. Calcium current block by (−)-pentobarbital, phenobarbital, and CHEB but not (+)-pentobarbital in acutely isolated hippocampal CA1 neurons: comparison with effects on GABA-activated Cl− current.
Fink K, Meder W, Dooley DJ, Göthert M. Inhibition of neuronal Ca2+ influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices.
Fink-Jensen A, Suzdak PD, Swedberg MD, Judge ME, Hansen L, Nielsen PG. The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats.
Fohlmeister JF, Adelman WJ Jr, Brennan JJ. Excitable channel currents and gating times in the presence of anticonvulsants ethosuximide and valproate.
Frahm C, Stief F, Zuschratter W, Draguhn A. Unaltered control of extracellular GABA-concentration through GAT-1 in the hippocampus of rats after pilocarpine-induced status epilepticus.
Freiman TM, Kukolja J, Heinemeyer J, Eckhardt K, Aranda H, Rominger A, et al. Modulation of K+-evoked [3H]-noradrenaline release from rat and human brain slices by gabapentin: involvement of KATP channels.
Gastaldi M, Bartolomei F, Massacrier A, Planells R, Robaglia-Schlupp A, Cau P. Increase in mRNAs encoding neonatal II and III sodium channel alpha-isoforms during kainate-induced seizures in adult rat hippocampus.
Gastaldi M, Robaglia-Schlupp A, Massacrier A, Planells R, Cau P. mRNA coding for voltage-gated sodium channel beta2 subunit in rat central nervous system: cellular distribution and changes following kainate-induced seizures.
Gebhardt C, Breustedt JM, Noldner M, Chatterjee SS, Heinemann U. The antiepileptic drug losigamone decreases the persistent Na+ current in rat hippocampal neurons.
Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α2δ subunit of a calcium channel.
Gibbs JW III, Shumate M, Coulter D. Differential epilepsy-associated alerations in postsynaptic GABAA receptor function in dentate granule and CA1 neurons.
Gibbs JW III, Sombati S, DeLorenzo RJ, Coulter DA. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons.
Golden PL, Pardridge WM. P-Glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries.
Golden PL, Pardridge WM. Brain microvascular P-glycoprotein and a revised model of multidrug resistance in brain.
Goldin AL, Barchi RL, Caldwell JH, Hofmann F, Howe JR, Hunter JC, et al. Nomenclature of voltage-gated sodium channels.
Gomora JC, Daud AN, Weiergraber M, Perez-Reyes E. Block of cloned human T-type calcium channels by succinimide antiepileptic drugs.
Gordey M, DeLorey TM, Olsen RW. Differential sensitivity of recombinant GABA(A) receptors expressed in Xenopus oocytes to modulation by topiramate.
Gryder DS, Rogawski MA. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons.
Harty TP, Rogawski MA. Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit.
Herrero AI, Del Olmo N, Gonzalez-Escalada JR, Solis JM. Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance.
Huai-Yun H, Secrest DT, Mark KS, Carney D, Brandquist C, Elmquist WF, et al. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells.
Huang CW, Huang CC, Liu YC, Wu SN. Inhibitory effect of lamotrigine on A-type potassium current in hippocampal neuron-derived H19-7 cells.
Huguenard JR. Low-threshold calcium currents in central nervous system neurons.
Huguenard JR. Block of T-type calcium channels is an important action of succinimide antiabsence drugs.
Isokawa M, Levesque MF. Increased NMDA responses and dendritic degeneration in human epileptic hippocampal neurons in slices.
Jeub M, Beck H, Siep E, Ruschenschmidt C, Speckmann EJ, Ebert U, et al. Effect of phenytoin on sodium and calcium currents in hippocampal CA1 neurons of phenytoin-resistant kindled rats.
Jolkkonen J, Mazurkiewicz M, Lahtinen H, Riekkinen P. Acute effects of gamma-vinyl GABA on the GABAergic system in rats as studied by microdialysis.
Kearney JA, Plummer NW, Smith MR, Kapur J, Cummins TR, Waxman SG, et al. A gain-of-function mutation in the sodium channel gene Scn2a results in seizures and behavioral abnormalities.
Kerb R, Aynacioglu AS, Brockmoller J, Schlagenhaufer R, Bauer S, Szekeres T, et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels.
Kerb R, Hoffmeyer S, Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2.
Kleckner NW, Glazewski JC, Chen CC, Moscrip TD. Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action.
Kohr G, De Koninck Y, Mody I. Properties of NMDA receptor channels in neurons acutely isolated from epileptic (kindled) rats.
Kuo CC. A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na+ channels.
Kuo CC, Lin BJ, Chang HR, Hsieh CP. Use-dependent inhibition of the N-methyl-D-aspartate currents by felbamate: a gating modifier with selective binding to the desensitized channels.
Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy.
Kwan P, Sills GJ, Butler E, Gant TW, Meldrum BS, Brodie MJ. Regional expression of multidrug resistance genes in genetically epilepsy-prone rat brain after a single audiogenic seizure.
Lacinova L. Pharmacology of recombinant low-voltage activated calcium channels.
Lampl I, Schwindt P, Crill W. Reduction of cortical pyramidal neuron excitability by the action of phenytoin on persistent Na+ current.
Lazarowski A, Sevlever G, Taratuto A, Massaro M, Rabinowicz A. Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy.
Leite JP, Cavalheiro EA. Effects of conventional antiepileptic drugs in a model of spontaneous recurrent seizures in rats.
Leresche N, Parri HR, Erdemli G, Guyon A, Turner JP, Williams SR, et al. On the action of the anti-absence drug ethosuximide in the rat and cat thalamus.
Löscher W, Horstermann D. Differential effects of vigabatrin, gamma-acetylenic GABA, aminooxyacetic acid, and valproate on levels of various amino acids in rat brain regions and plasma.
Löscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs.
Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters.
Löscher W, Cramer S, Ebert U. Selection of phenytoin responders and nonresponders in male and female amygdala-kindled Sprague-Dawley rats.
Lossin C, Wang DW, Rhodes TH, Vanoye CG, George AL Jr. Molecular basis of an inherited epilepsy.
Lucas PT, Meadows LS, Nicholls J, Ragsdale DS. An epilepsy mutation in the beta1 subunit of the voltage-gated sodium channel results in reduced channel sensitivity to phenytoin.
Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam.
Madeja M, Margineanu DG, Gorji A, Siep E, Boerrigter P, Klitgaard H, et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action?
Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine.
Marchi N, Hallene KL, Kight KM, Cucullo L, Moddel G, Bingaman W, et al. Significance of MDR1 and multiple drug resistance in refractory human epileptic brain.
Martin D, McNamara JO, Nadler JV. Kindling enhances sensitivity of CA3 hippocampal pyramidal cells to NMDA.
McClelland D, Evans RM, Barkworth L, Martin DJ, Scott RH. A study comparing the actions of gabapentin and pregabalin on the electrophysiological properties of cultured DRG neurones from neonatal rats.
McLean MJ, Macdonald RL. Sodium valproate, but not ethosuximide, produces use- and voltage- dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture.
McLean MJ, Schmutz M, Wamil AW, Olpe HR, Portet C, Feldmann KF. Oxcarbazepine: mechanisms of action.
McLean MJ, Bukhari AA, Wamil AW. Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture.
Mody I, Heinemann U. NMDA receptors of dentate gyrus granule cells participate in synaptic transmission following kindling.
Mody I, Pearce RA. Diversity of inhibitory neurotransmission through GABA(A) receptors.
Niespodziany I, Klitgaard H, Margineanu DG. Is the persistent sodium current a specific target of anti-absence drugs?
Nissinen JPT, Pitkänen A. An animal model with spontaneous seizures: a new tool for testing the effects of antiepileptic compounds.
Nobile M, Lagostena L. A discriminant block among K+ channel types by phenytoin in neuroblastoma cells.
Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK. Carbamazepine is not a substrate for P-glycoprotein.
Pardridge WM, Golden PL, Kang YS, Bickel U. Brain microvascular and astrocyte localization of P-glycoprotein.
Poolos NP, Migliore M, Johnston D. Pharmacological upregulation of h-channels reduces the excitability of pyramidal neuron dendrites.
Potschka H, Löscher W. In-vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats.
Potschka H, Fedrowitz M, Löscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain.
Potschka H, Fedrowitz M, Löscher W. P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats.
Potschka H, Fedrowitz M, Löscher W. Brain access and anticonvulsant efficacy of carbamazepine, lamotrigine, and felbamate in ABCC2/MRP2-deficient TR- rats.
Potschka H, Fedrowitz M, Löscher W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity.
Qian J, Noebels JL. Topiramate alters excitatory synaptic transmission in mouse hippocampus.
Ragsdale DS, Avoli M. Sodium channels as molecular targets for antiepileptic drugs.
Ragsdale DS, Scheuer T, Catterall WA. Frequency and voltage-dependent inhibition of type IIA Na+ channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs.
Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, et al. Choroid plexus epithelial expression of MDR1 P-glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier.
Reckziegel G, Beck H, Schramm J, Urban BW, Elger CE. Carbamazepine effects on Na+ currents in human dentate granule cells from epileptogenic tissue.
Regesta G, Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies.
Regina A, Koman A, Piciotti M, El Hafny B, Center MS, Bergmann R, et al. Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells.
Remy S, Gabriel S, Urban BW, Dietrich D, Lehmann TN, Elger CE, et al. A novel mechanism underlying drug-resistance in chronic epilepsy.
Remy S, Urban BW, Elger CE, Beck H. Anticonvulsant pharmacology of voltage-gated Na+ channels in hippocampal neurons of control and chronically epileptic rats.
Rho JM, Donevan SD, Rogawski MA. Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate.
Rhodes TH, Lossin C, Vanoye CG, Wang DW, George AL Jr. Noninactivating voltage-gated sodium channels in severe myoclonic epilepsy of infancy.
Rizzi M, Caccia S, Guiso G, Richichi C, Corter JA, Aronica E, et al. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance.
Robinson RB, Siegelbaum SA. Hyperpolarization-activated cation currents: from molecules to physiological function.
Rogers CJ, Twyman RE, Macdonald RL. Benzodiazepine and β-carboline regulation of single GABAA receptor channels of mouse spinal neurones in culture.
Rudolph U, Crestani F, Benke D, Brunig I, Benson JA, Fritschy JM, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes.
Rudolph U, Crestani F, Mohler H. GABA(A) receptor subtypes: dissecting their pharmacological functions.
Sanabria ERG, Su H, Yaari Y. Initiation of network bursts by Ca2+-dependent intrinsic bursting in the rat pilocarpine model of temporal lobe epilepsy.
Schinkel AH, Wagenaar E, Mol CA, Van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.
Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smitt JJ, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.
Schmutz M, Brugger F, Gentsch C, McLean MJ, Olpe HR. Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action.
Schumacher TB, Beck H, Steinhauser C, Schramm J, Elger CE. Effects of phenytoin, carbamazepine, and gabapentin on calcium channels in hippocampal granule cells from patients with temporal lobe epilepsy.
Schwarz JR, Grigat G. Phenytoin and carbamazepine: potential- and frequency-dependent block of Na currents in mammalian myelinated nerve fibers.
Segal MM, Douglas AF. Late sodium channel openings underlying epileptiform activity are preferentially diminished by the anticonvulsant phenytoin.
Shah MM, Anderson AE, Leung V, Lin X, Johnston D. Seizure-induced plasticity of h channels in entorhinal cortical layer III pyramidal neurons.
Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1.
Sills GJ, Kwan P, Butler E, de Lange EC, van den Berg DJ, Brodie MJ. P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice.
Silverman JA, Raunio H, Gant TW, Thorgeirsson SS. Cloning and characterization of a member of the rat multidrug resistance (mdr) gene family.
Sisodiya SM, Heffernan J, Squier MV. Over-expression of P-glycoprotein in malformations of cortical development.
Sisodiya SM, Lin WR, Squier MV, Thom M. Multidrug-resistance protein 1 in focal cortical dysplasia.
Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy.
Soranzo N, Cavalleri GL, Weale ME, Wood NW, Despondt C, Marguerie R, et al. Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene.
Spadoni F, Hainsworth AH, Mercuri NB, Caputi L, Martella G, Lavaroni F, et al. Lamotrigine derivatives and riluzole inhibit INa,P in cortical neurons.
Spampanato J, Kearney JA, de Haan G, McEwen DP, Escayg A, Aradi I, et al. A novel epilepsy mutation in the sodium channel SCN1A identifies a cytoplasmic domain for beta subunit interaction.
Sperk G, Furtinger S, Schwarzer C, Pirker S. GABA and its receptors in epilepsy.
Stefani A, Pisani A, De Murtas M, Mercuri NB, Marciani MG, Calabresi P. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents.
Stefani A, Spadoni F, Bernardi G. Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies.
Stefani A, Spadoni F, Bernardi G. Voltage-activated calcium channels: targets of antiepileptic drug therapy?
Stefani A, Spadoni F, Bernardi G. Gabapentin inhibits calcium currents in isolated rat brain neurons.
Study RE, Barker JL. Diazepam and (−)-pentobarbital: fluctuation analysis reveals different mechanisms for potentiation of gamma-aminobutyric acid responses in cultured central neurons.
Su H, Alroy G, Kirson ED, Yaari Y. Extracellular calcium modulates persistent sodium current-dependent intrinsic bursting in rat hippocampal neurons.
Su H, Sochivko D, Becker A, Chen J, Jiang Y Yaari Y, et al. Upregulation of a T-type Ca2+ channel causes a long-lasting modification of neuronal firing mode after status epilepticus.
Subramaniam S, Rho JM, Penix L, Donevan SD, Fielding RP, Rogawski MA. Felbamate block of the N-methyl-D-aspartate receptor.
Surges R, Freiman TM, Feuerstein TJ. Gabapentin increases the hyperpolarization-activated cation current Ih in rat CA1 pyramidal cells.
Suzuki S, Kawakami K, Nishimura S, Watanabe Y, Yagi K, Seino M, et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex.
Taglialatela M, Ongini E, Brown AM, Di Renzo G, Annunziato L. Felbamate inhibits cloned voltage-dependent Na+ channels from human and rat brain.
Tan NC, Heron SE, Scheffer IE, Pelekanos JT, McMahon JM, Vears DF, et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy.
Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.
Tatulian L, Delmas P, Abogadie FC, Brown DA. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine.
Taverna S, Mantegazza M, Franceschetti S, Avanzini G. Valproate selectively reduces the persistent fraction of Na+ current in neocortical neurons.
Taverna S, Sancini G, Mantegazza M, Franceschetti S, Avanzini G. Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate.
Thompson SM, Gähwiler BH. Effects of the GABA uptake inhibitor tiagabine on inhibitory synaptic potentials in rat hippocampal slice cultures.
Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy.
Todorovic SM, Lingle CJ. Pharmacological properties of T-type Ca2+ current in adult rat sensory neurons: effects of anticonvulsant and anesthetic agents.
Todorovic SM, Perez-Reyes E, Lingle CJ. Anticonvulsants but not general anesthetics have differential blocking effects on different T-type current variants.
Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital.
Twyman RE, Rogers CJ, Macdonald RL. Pentobarbital and picrotoxin have reciprocal actions on single GABAA receptor channels.
Ueda K, Shimabuku AM, Konishi H, Fujii Y, Takebe S, Nishi K, et al. Functional expression of human P-glycoprotein in Schizosaccharomyces pombe.
Van Vliet EA, Aronica E, Redeker S, Gorter JA. Expression and cellular distribution of major vault protein: a putative marker for pharmacoresistance in a rat model for temporal lobe epilepsy.
Volk HA, Löscher W. Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures.
Volk HA, Burkhardt K, Potschka H, Chen J, Becker A, Löscher W. Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures.
Vreugdenhil M, Van Veelen CWM, Van Rijen PC, Da Silva FHL, Wadman WJ. Effect of valproic acid on sodium currents in cortical neurons from patients with pharmaco-resistant temporal lobe epilepsy.
Vreugdenhil M, Wadman WJ. Modulation of sodium currents in rat CA1 neurons by carbamazepine and valproate after kindling epileptogenesis.
Wang SJ, Huang CC, Hsu KS, Tsai JJ, Gean PW. Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones.
Weiss J, Kerpen CJ, Lindenmaier H, Dormann SM, Haefeli WE. Interaction of antiepileptic drugs with human P-glycoprotein in vitro.
Whitaker WR, Faull RL, Dragunow M, Mee EW, Emson PC, Clare JJ. Changes in the mRNAs encoding voltage-gated sodium channel types II and III in human epileptic hippocampus.
White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold.
White HS, Harmsworth WL, Sofia RD, Wolf HH. Felbamate modulates the strychnine-insensitive glycine receptor.
Willow M, Gonoi T, Catterall WA. Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells.
Wozny C, Kivi A, Lehmann TN, Dehnicke C, Heinemann U, Behr J. Comment on ‘On the origin of interictal activity in human temporal lobe epilepsy in vitro’.
Wu Y, Wang W, Richerson GB. Vigabatrin induces tonic inhibition via GABA transporter reversal without increasing vesicular GABA release.
Xie X, Dale TJ, John VH, Cater HL, Peakman TC, Clare JJ. Electrophysiological and pharmacological properties of the human brain type IIA Na+ channel expressed in a stable mammalian cell line.
Xie X, Lancaster B, Peakman T, Garthwaite J. Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na+ channels and with native Na+ channels in rat hippocampal neurones.
Yaari Y, Hamon B, Lux HD. Development of two types of calcium channels in cultured mammalian hippocampal neurons.
Yue C, Yaari Y. KCNQ/M channels control spike after depolarization and burst generation in hippocampal neurons.
Zhang L, Ong WY, Lee T. Induction of P-glycoprotein expression in astrocytes following intracerebroventricular kainate injections.
Zhang X, Velumian AA, Jones OT, Carlen PL. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate.
Zona C, Avoli M. Effects induced by the antiepileptic drug valproic acid upon the ionic currents recorded in rat neocortical neurons in cell culture.
Zona C, Avoli M. Lamotrigine reduces voltage-gated sodium currents in rat central neurons in culture.
Zona C, Ciotti MT, Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells.
Zona C, Niespodziany I, Marchetti C, Klitgaard H, Bernardi G, Margineanu DG. Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents.